Trials / Completed
CompletedNCT00272454
Cilostazol in Acute Ischemic Stroke Treatment (CAIST)
The Double-Blind, Randomized, Multi-Center, and Active Controlled Trial for Efficacy and Safety of Cilostazol in Acute Ischemic Stroke
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 468 (estimated)
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 30 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to study efficacy and safety of cilostazol use in patients with acute ischemic stroke.
Detailed description
Stroke is a leading cause of death and elderly disability in developed countries. However, treatment of acute stroke is limited except thrombolytic therapy in hyperacute stroke within several hours. Currently, aspirin is widely used in spite of its small benefit compared to bleeding complications. Cilostazol will be compared to aspirin in acute stroke patients in terms of functional outcome at 3 months, efficacy to prevent stroke recurrence, and safety for bleeding complications.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cilostazol | |
| DRUG | Aspirin |
Timeline
- Start date
- 2006-01-01
- Completion
- 2008-09-01
- First posted
- 2006-01-06
- Last updated
- 2009-12-16
Locations
12 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00272454. Inclusion in this directory is not an endorsement.